Future Medicine: Biomarkers in Medicine This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Potential biomarkers in breast cancer drug development: application of the biomarker qualification evidentiary framework
Biomark Med. 2024 Mar 15. doi: 10.2217/bmm-2023-0048. Online ahead of print.ABSTRACTBreast cancer treatments have evolved rapidly, and clinically meaningful biomarkers have been used to guide therapy. These biomarkers hold utility within the drug development process to increase the efficiency and effectiveness. To this purpose, the US FDA developed an evidentiary framework. Literature searches conducted of literature published between 2016 and 2022 identified biomarkers in breast cancer. These biomarkers were reviewed for drug development utility through the biomarker qualification evidentiary framework. In the breast canc...
Source: Future Medicine: Biomarkers in Medicine - March 15, 2024 Category: Internal Medicine Authors: Eric Wang Mackenzie Henderson Priyanka Yalamanchili Jenilee Cueto Zahidul Islam Charles Dharmani Maribel Salas Source Type: research

Evaluation of Naples prognostic score to predict long-term mortality in patients with pulmonary embolism
Conclusion: This study highlights that NPS may have the potential to predict long-term mortality in APE patients.PMID:38487977 | DOI:10.2217/bmm-2023-0741 (Source: Future Medicine: Biomarkers in Medicine)
Source: Future Medicine: Biomarkers in Medicine - March 15, 2024 Category: Internal Medicine Authors: Levent Pay Tu ğba Çetin K ıvanç Keskin Şeyda Dereli Ozan Tezen Ahmet Ç Yumurtaş Zeynep Kolak Semih Eren Faysal Şaylık Tufan Çınar Mert I Hay ıroğlu Source Type: research

Diagnostic predictability of serum miR-4793-3p and miR-1180-3p expression in community-acquired pneumonia
Conclusion: Increased levels of miR-4793-3p and miR-1180-3p may indicate severe pneumonia development. Plasma miRNA profiling enables early prediction of severe CAP, aiding therapeutic decisions.PMID:38456294 | DOI:10.2217/bmm-2023-0463 (Source: Future Medicine: Biomarkers in Medicine)
Source: Future Medicine: Biomarkers in Medicine - March 8, 2024 Category: Internal Medicine Authors: Rong Chai Cihang Zhou Zhenli Hu Jingjing Hu Source Type: research

Pharmacogenomic biomarkers in coronary artery disease: a narrative review
Biomark Med. 2024 Mar 8. doi: 10.2217/bmm-2023-0476. Online ahead of print.ABSTRACTCoronary artery disease (CAD) has a high mortality rate. Despite various therapeutic targets, non-responsiveness to drugs remains a prevalent issue. Pharmacogenomics assesses the way an individual's genetic attributes affect their likely response to drug therapy. Single-nucleotide polymorphisms play a crucial role in determining these outcomes. This review offers an overview of single-nucleotide polymorphisms investigated in clinical studies and their associations with drug response/nonresponse in the treatment of CAD. A total of 104 studies...
Source: Future Medicine: Biomarkers in Medicine - March 8, 2024 Category: Internal Medicine Authors: Pamila Dua Sandeep Seth Bhavana Prasher Mitali Mukerji Subir Kumar Maulik K H Reeta Source Type: research

Lipid accumulation product is a valid predictor of hepatic steatosis and nonalcoholic fatty liver disease
Conclusion: LAP is an ideal biomarker of hepatic steatosis and NAFLD.PMID:38456353 | DOI:10.2217/bmm-2023-0725 (Source: Future Medicine: Biomarkers in Medicine)
Source: Future Medicine: Biomarkers in Medicine - March 8, 2024 Category: Internal Medicine Authors: Qiaoli Huang Xuying Tan Qiongmei Wu Hanqing Zhao Hangjun Chen Xinxue Yu Jinting Wang Xueyi Huang Yurong Huang Jun Wei Feng Wu Huilian Zhu Lijun Wang Source Type: research